Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast08
NCT04556773Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label trial of trastuzumab deruxtecan in breast cancer (5 arms), sponsored by AstraZeneca. Primary endpoints: Occurrence of adverse events at 24 months and Occurrence of serious adverse events at 24 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04556773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556773.